12 completed, 11 terminated, 5 recruiting, 2 active not recruiting. 36 Phase 2, 12 Phase 1.
Follow Lymphopenia: new trials by email Literature Review of Lymphopenia trials Research Report on Lymphopenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors PRaG-1, Placebo - Solid Cancer, Lymphopenia | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | 127 | 2025-12-01 | 2026-01-09 |
| PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) PD -1/PD-L1 monoclonal antibody - Solid Cancer, Lymphopenia | Phase 2 | Recruiting | Second Affiliated Hospital of Soochow University | 65 | 2025-12-01 | 2026-10-27 |
| A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia Recombinant human interleukin (IL) 7-hyFc - Idiopathic CD4 Lymphopenia | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2024-11-06 | 2026-10-19 |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections - Hematological Malignancy, Lymphocytopenia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 50 | 2024-09-01 | 2024-09-19 |
| Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Radiation Therapy, Temozolomide Oral Product - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | John Flickinger | 2 | 2021-12-14 | 2025-06-18 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) Interleukin-7, PLACEBO - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 4 | 2021-03-01 | 2024-04-12 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 10 | 2020-12-20 | 2024-04-11 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 26 | 2020-09-15 | 2022-04-08 |
| Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection Thymalfasin - Covid19 | Phase 2 | Terminated | Rhode Island Hospital | 56 | 2020-09-10 | 2023-02-14 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort Interleukin-7, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 34 | 2020-06-08 | 2022-04-08 |
| InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort Interleukin-7, Placebos - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 35 | 2020-05-14 | 2022-04-07 |
| Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome Romiplostim, Eltrombopag - Wiskott-Aldrich Syndrome | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 30 | 2019-11-05 | 2020-05-06 |
| Pyridostigmine as Immunomodulator in People Living With HIV Pyridostigmine Bromide, Placebo - HIV-1-infection, CD4+ T Lymphocytopenia | Phase 2 | Suspended | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 60 | 2019-07-01 | 2020-04-10 |
| Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients CYT107, Placebos - Sepsis, Severe | Phase 2 | Terminated | Revimmune | 21 | 2019-06-01 | 2021-10-27 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Thiotepa--single daily dose, Thiotepa--escalated dose - Bone Marrow Failure Syndrome, Thalassemia | Phase 1 / Phase 2 | Completed | University of Florida | 6 | 2018-06-15 | 2023-09-15 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission | Phase 2 | Terminated | Roswell Park Cancer Institute | 31 | 2017-12-07 | 2025-07-04 |
| A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients G-CSF for Conditioning before HSCT., Plerixafor for Conditioning before HSCT. - Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 30 | 2016-06-01 | 2018-12-12 |
| Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Autologous CD34+ cells transduced with WASP lentiviral vector - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Active not recruiting | Genethon | 10 | 2014-09-01 | 2021-06-03 |
Showing 20 of 36. Sign in to see all of them.
Wiskott-Aldrich Syndrome (18) · Granulomatous Disease, Chronic (7) · Anemia, Diamond-Blackfan (6) · COVID-19 (6) · Anemia, Sickle Cell (5) · Severe Combined Immunodeficiency (5) · Thalassemia (5) · Congenital amegakaryocytic thrombocytopenia (4) · Lymphohistiocytosis, Hemophagocytic (4) · Lymphoproliferative Disorders (4) · Primary Immunodeficiency Diseases (4) · Thrombocytopenia (4) · Chediak-Higashi Syndrome (3) · Common Variable Immunodeficiency (3)
Hematologic Diseases (36) · Hemic and Lymphatic Diseases (36) · Leukocyte Disorders (36) · Leukopenia (36) · Cytopenia (35) · Immune System Diseases (35) · Immunologic Deficiency Syndromes (33) · Blood Coagulation Disorders (18) · Blood Coagulation Disorders, Inherited (18) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Genetic Diseases, X-Linked (18) · Hemorrhagic Disorders (18) · Genetic Diseases, Inborn (16) · Primary Immunodeficiency Diseases (14)
Interleukin-7 (6) · Sodium Chloride (5) · fludarabine phosphate (4) · Melphalan (3) · Peripheral Blood Stem Cell Transplantation (3) · Whole-Body Irradiation (3) · fludarabine (3) · ALT-803 (2) · Cyclophosphamide (2) · Methotrexate (2) · Mycophenolic Acid (2) · Tacrolimus (2) · Thiotepa (2) · Thymalfasin (2) · eltrombopag (2)
Revimmune (6) · Genethon (3) · Children's Hospital Los Angeles (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · ImmunityBio, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Paul Szabolcs (2) · Roswell Park Cancer Institute (2) · Second Affiliated Hospital of Soochow University (2) · Centre Leon Berard (1) · David Williams (1) · Fondazione Telethon (1) · Fred Hutchinson Cancer Center (1) · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1) · John Flickinger (1)
United States (18) · France (5) · China (3) · United Kingdom (3) · Russia (2) · Brazil (1) · Italy (1) · Mexico (1) · South Korea (1)
Paul Szabolcs, MD (2) · Alexei Maschan, Professor (1) · Andrea Lisco, M.D. (1) · Biljana Horn, MD (1) · Dmitry Balashov (1) · Eleftherios Mylonakis, MD PhD FIDSA (1) · George Chen (1) · Hisham Abdel-Azim, MD (1) · Hyo Seop Ahn, Ph. D (1) · Isabelle Ray Coquart (1) · James B Bussel, MD (1) · Jennifer Whangbo, M.D. (1) · John Flickinger, MD (1)
PMID 39903535, PMID 32031570, PMID 32171076, PMID 29515037, PMID 35075289, PMID 23053510, PMID 10561360, PMID 10737767, PMID 12010786, PMID 12411295, PMID 12610500, PMID 12628464, PMID 12759326, PMID 12816983, PMID 14557216, PMID 14615453, PMID 15503313, PMID 15569976, PMID 15629410, PMID 15841203, PMID 15905493, PMID 16249702, PMID 16557261, PMID 16699374, PMID 17135638, PMID 17273548, PMID 17320482, PMID 18573906, PMID 18946659, PMID 19244125, PMID 19287090, PMID 19380868, PMID 19396174, PMID 19549917, PMID 19645607, PMID 19808962, PMID 19933849, PMID 20651586, PMID 21403129, PMID 21921156, PMID 22550117, PMID 22632127, PMID 25459642, PMID 26224646, PMID 26675348, PMID 28716862, PMID 29093707, PMID 29550630, PMID 30981783, PMID 31599480
2009 (2), P30CA015704 (1)